Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 11/20 | 0.70 |
| ▸ | CDK2 | P24941 | 4/20 | 0.70 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.70 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.70 |
| ▸ | JAK2 | O60674 | 2/20 | 0.70 |
| ▸ | JAK1 | P23458 | 2/20 | 0.70 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.58 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.58 |
| ▸ | MARK3 | P27448 | 1/20 | 0.58 |
| ▸ | CLK2 | P49760 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.58 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.58 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.58 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.58 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.58 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18932061 | 0.87 | JAK2 (0.60) | FLT3CDK2CCNA2CCNA1JAK2 | |
| SCHEMBL4007094 | 0.85 | FLT3 (0.72) | FLT3CDK2CCNA2CCNA1JAK2 | |
| SCHEMBL18828966 | 0.85 | JAK2 (0.57) | FLT3CDK2CCNA2CCNA1JAK2 | |
| SCHEMBL18812674 | 0.85 | JAK2 (0.57) | FLT3CDK2CCNA2CCNA1JAK2 | |
| SCHEMBL18812672 | 0.85 | JAK2 (0.57) | FLT3CDK2CCNA2CCNA1JAK2 | |
| SCHEMBL4530485 | 0.84 | FLT3 (0.75) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL5945798 | 0.84 | FLT3 (0.70) | FLT3CDK2CCNA2CCNA1JAK2 | |
| SCHEMBL5945795 | 0.84 | FLT3 (0.71) | FLT3CDK2CCNA2CCNA1JAK2 | |
| SCHEMBL30912934 | 0.84 | FLT3 (0.70) | FLT3CDK2CCNA2CCNA1JAK2 | |
| SCHEMBL5945718 | 0.84 | FLT3 (0.70) | FLT3CDK2CCNA2CCNA1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | FLT3 815/4885CDK2 176/4885CCNA2 538/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | FLT3 702/4885CDK2 194/4885CCNA2 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.